Kexing Biopharm’s Iicensed-in Bevacizumab Receives Marketing Authorization in Mexico

Article source：Jul 20,2026View： 742

Recently, the bevacizumab biosimilar introduced by Kexing Biopharm (688136.SH) and developed by BioDlink was approved for marketing by Mexico’s regulatory authority, COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios).

Bevacizumab is an important therapeutic agent in oncology, with indications covering multiple high-incidence solid tumors, including metastatic colorectal cancer, advanced non-small cell lung cancer (NSCLC), recurrent glioblastoma, ovarian cancer, and cervical cancer. As a result, it addresses significant and widespread clinical needs.

Since the two companies established their overseas commercialization partnership for the bevacizumab biosimilar, Kexing Biopharm has successfully secured marketing approvals for the product in multiple countries, including Nigeria, Pakistan, Colombia, Bolivia, Syria, and Indonesia. Kexing Biopharm’s end-to-end overseas commercialization capabilities have become one of the key advantages enabling the product’s rapid entry into international markets. On the manufacturing and supply side, BioDlink Biopharm’s commercial production line for bevacizumab has obtained GMP certifications from several countries, including Brazil, Argentina, Indonesia, and Egypt, providing a strong foundation for product quality and supply reliability.

Currently, through its platform-based global expansion strategy of “Global Product Selection + Global Market Coverage,” Kexing Biopharm has established overseas commercialization partnerships with multiple pharmaceutical companies. Looking ahead, the company will continue to accelerate the international expansion of high-quality Chinese biopharmaceutical products, benefiting more patients worldwide.